🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
XER
$XERS
🔒 US EquitiesXeris Biopharma Holdings Inc
AVG HISTORICAL GAP
+2.55%
MAX GAP RECORD
+22.59%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $XERS
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$XERS
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 05, 2026 Earnings Release 2026-11-05 (BEFORE OPEN (07:00)) | 🔮 UPCOMING 🔒 |
| Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN) |
-11.34%
|
| May 07, 2026 Earnings Release 2026-05-07 (BEFORE OPEN) |
+5.18%
|
| Mar 02, 2026 Earnings Release 2026-03-02 (BEFORE OPEN) |
+15.69%
|
| Nov 06, 2025 Earnings Release 2025-11-06 (BEFORE OPEN) |
-14.89%
|
| Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN) |
+22.59%
|
| May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN) |
+2.09%
|
| Mar 06, 2025 Earnings Release 2025-03-06 (BEFORE OPEN) |
+9.81%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
6.8%
Bullish Gaps (10)
Bearish Gaps (5)
Neutral / Flat (0)
📖 Intelligence Summary
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗